Although a growing body of evidence supports the role of SGLT2 inhibitors as disease-modifying agents for CKD, their use is still limited in clinical practice partially due to their cost (Aggarwal et al., 2022). The gene discussed is SLC5A2; the disease is chronic kidney disease.